INTERPRETATION AND APPLICATION OF PHARMACOECONOMIC DATA

A. GENERAL REVIEWS
B. REVIEWING/CRITIQUING RESEARCH ARTICLES/PAPERS
 


A. GENERAL REVIEWS
 
  1. Barbieri M, Drummond M, Willke R, et al. Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability.
     Value in Health 2005;8(1):10-23
    Review 
     
  2. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? (eng; includes abstract) By Brinsmead R, Journal Of Clinical Pharmacy And Therapeutics [J Clin Pharm Ther], 2003 Aug; Vol. 28 (4), pp. 339-46; PMID: 12911687 

  3. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin. (eng; includes abstract) By Lopert R, Journal Of Clinical Pharmacy And Therapeutics [J Clin Pharm Ther], 2003 Jun; Vol. 28 (3), pp. 243-9; PMID: 12795784
     
  4. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis--when are two therapies equal? (eng; includes abstract) By Newby D, Journal Of Clinical Pharmacy And Therapeutics [J Clin Pharm Ther], 2003 Apr; Vol. 28 (2), pp. 145-50; PMID: 12713612
     
  5. Basskin L. “Pharmacoeconomics and the Formulary Decision-Making Process. Formulary. May 1998;33:459-466
     
  6. Eddy DM. “Clinical decision making: from theory to practice. Applying cost-effectiveness analysis. The inside story.” JAMA. Nov 11,1992;268(18):2575-82.
     
  7. Neumann PJ, Claxton K, Weinstein MC. “The FDA's regulation of health economic information.” Health Aff (Millwood). Sept/Oct 2000;19(5):129-37.
     
  8. Eichler HG, Kong SX, Gerth WC, et al. “Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are the cost-effectiveness thresholds expected to emerge?” Value Health. Sept-Oct 2004;7(5):518-528.
     
  9. Fry RN, Avey SG, Sullivan SD. “The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard—A Foundation for Managed Care Pharmacy Task Force report.” Value Health. Sept/Oct 2003;6(5):505-21.
     
  10. Garber AM. “Cost-effectiveness and evidence evaluation as criteria for coverage policy.” Health Aff (Millwood). Jan-Jun 2004;Suppl:W4-284-96.
     
  11. Moayyedi P, Mason J. “Cost-Utility and Cost-Benefit Analyses: How Did We Get Here and Where are We Going?” European Journal of Gastroenterology and Hepatology. 2004;16(6):527-534.
     
  12. Rawlins MD, Culyer AJ. “National Institute for Clinical Excellence and its value judgments.” BMJ. July 24, 2004;329:224-7.
     
  13. Russell LB. “The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.” JAMA. Oct 9, 1996;276(14):1172-7.
     
  14. Siegel JE. “Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.” JAMA. Oct 23, 1996;276(16):1339-41.
     
  15. Vermeulen LC, Beis SJ, Cano SB. “Applying Outcomes Research in Improving the Medication Use Process.” Am J Health Syst Pharm. 2000;57:2277-82.
     
  16. Weinstein MC. “Recommendations of the Panel on Cost-effectiveness in Health and Medicine.” JAMA. Oct 16, 1996;276(15):1253-8.

B. REVIEWING/CRITIQUING RESEARCH ARTICLES/PAPERS
 
  1. Sackett D., Straus S., et al. Evidence-Based Medicine: How to Practice and Teach EBM (2nd ed.). Edinburgh; New York: Churchill Livingstone, 2000.
    Review
     
  2. Abarca J. Assessing Pharmacoeconomic Studies. Chapter 16 in: Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics (3rd ed.). Cincinnati: Harvey Whitney Books Co., 2005.
    Review
     
  3. Critical Assessment of Economic Evaluation. Chapter 3 in Drummond MF, Sculpher MJ, Torrance, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes
    (3rd ed.). Oxford, New York: Oxford University Press, 2005.
    Review
     
  4. Doubilet P, Weinstein MC, McNeil BJ. “Use and misuse of the term “cost effective” in medicine.” New Eng J Med. Jan 23, 1986;314(4):253-6.
     
  5. Drummond MF, Richardson SW, O’Brien BJ, et al. “Users’ Guides to the Medical Literature. XIII. How to Use an Article on Economic Analysis of Clinical Practice. A. Are the Results of the Study Valid? Evidence-Based Medicine Working Group.” JAMA. May 21, 1997;277(19):1552-7.
     
  6. O’Brien BJ, Heyland, Richardson SW, et al. “Users’ Guides to the Medical Literature. XIII. How to Use an Article on Economic Analysis of Clinical Practice. B. What Are the Results and Will They Help Me in Caring for My Patients? Evidence-Based Medicine Working Group.” JAMA. June 11, 1997;277(22):1802-6.
     
  7. Sanchez LA. “Applied Pharmacoeconomics: Evaluation and Use of Pharmacoeconomic Data from the Literature.” Am J Health-Syst Pharm. Aug 15, 1999;56(16):1630-40.
     
  8. Weinstein MC, O'Brien B, Hornberger J, et al. “Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.” Value Health. Jan/Feb 2003;6(1):9-17.
     

Educator's Tool Kit main page
 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.